Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease

Marras et al. report a low number needed to treat and high number needed to harm supporting addition of amikacin liposome inhalation suspension to guideline-based treatments in patients with treatment-refractory Mycobacterium avium complex lung disease https://bit.ly/3tPFW7D

Detalles Bibliográficos
Autores principales: Marras, Theodore K., Hassan, Mariam, Mange, Kevin C., Ciesielska, Monika, Murthy, Shilpa Dhar, Jumadilova, Zhanna, Chatterjee, Anjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271752/
https://www.ncbi.nlm.nih.gov/pubmed/35821755
http://dx.doi.org/10.1183/23120541.00623-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271752/
https://www.ncbi.nlm.nih.gov/pubmed/35821755
http://dx.doi.org/10.1183/23120541.00623-2021

Ejemplares similares